Difference between revisions of "Combining-Carbamazepine-Lamotrigine"
From Psychiatrienet
(Created page with '{{Drugcombi | base = carbamazepine | add = lamotrigine == '''General information''' == * Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent in...') |
|||
| Line 2: | Line 2: | ||
| base = carbamazepine | | base = carbamazepine | ||
| add = lamotrigine | | add = lamotrigine | ||
| − | + | ||
| + | | General information = | ||
* Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4 and UDP-glucuronosyltransferases. | * Carbamazepine is principally metabolized by CYP3A4 (also CYP2C8), but is also a potent inducer of CYP1A2, CYP3A4 and UDP-glucuronosyltransferases. | ||
* Lamoptrigine is principally metabolised by UDP-glucuronosyltransferases. | * Lamoptrigine is principally metabolised by UDP-glucuronosyltransferases. | ||
* This combination of drugs may have possible synergistic effects. However, the pharmacokinetic drug interactions will influence the plasma levels. | * This combination of drugs may have possible synergistic effects. However, the pharmacokinetic drug interactions will influence the plasma levels. | ||
| − | + | | Combination = | |
* Carbamazepine can reduce lamotrigine serum concentration considerably. Add lamotrigine according to the general dosing advice. | * Carbamazepine can reduce lamotrigine serum concentration considerably. Add lamotrigine according to the general dosing advice. | ||
| − | + | | Caution = | |
Abrupt stop of carbamazepine can cause serious lamotrigine rash as lamotrigine levels increase. <ref name="torrentc"> {{Pubmed|12648898|Koch HJ et al. Clinically relevant reduction of lamotrigine concentrations by | Abrupt stop of carbamazepine can cause serious lamotrigine rash as lamotrigine levels increase. <ref name="torrentc"> {{Pubmed|12648898|Koch HJ et al. Clinically relevant reduction of lamotrigine concentrations by | ||
carbamazepine. J Clin Psychiatry 2005;66:400-1}}</ref> | carbamazepine. J Clin Psychiatry 2005;66:400-1}}</ref> | ||
}} | }} | ||
Revision as of 15:25, 3 March 2010
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
Adding lamotrigine to carbamazepine.
General information- Carbamazepine is principally metabolized by CYP3A4, and is a potent inducer of CYP1A2, CYP2C9, CYP3A4 and UDP-glucuronosyltransferases.
- Lamotrigine is principally metabolised by UDP-glucuronosyltransferases.
- ↑ WHO Collaborating Centre for Drug Statistics Methodology ATC=N03AF01
- ↑ 2.0 2.1 Farmacotherapeutisch Kompas; Toxicologie (dutch)
- ↑ 3.0 3.1 Farmacotherapeutisch Kompas - carbamazepine (dutch)
Cite error: Invalid
<ref>tag; name "ftk" defined multiple times with different content - ↑ KNMP; Informatorium Medicamentorum 2023; Monografie "carbamazepine" (Dutch)
- ↑ Drugs.com lamotrigine
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
